Cerebral Stroke
Conditions
Keywords
acute ischemic stroke
Brief summary
The objective of this trial is to visualize blood brain barrier function and metabolic changes in the first days after ischemic stroke with new investigational MRI sequences.
Detailed description
In this study the investigators will be examining acute ischemic stroke patients on the first and second day after symptom onset using repetitive MRI examinations to visualize blood brain barrier function and metabolic changes of the brain in 5 sub-projects, each containing a specific MRI protocol with one of the following new MRI sequences: 1. T1-Dynamics (measuring disruptions of the blood-brain barrier) 2. pH-imaging (measuring metabolic changes, acidosis) 3. Resting-state MRI (measuring changes in the cerebral perfusion) 4. Quantitative MRI-Angiography (quantification of blood flow in single vessels) 5. Diffusion Tensor Imaging (DTI) for patients with Anterior Choroidal Artery (AChA)-Infarcts (quantification of damage of white matter tracts) Each sub-projects will be conducted in blocks of a specific time span. Morphological outcome will be assessed at day 5-7. Clinical outcome will be assessed at day 5-7 and day 90. The association of the new imaging parameter with the clinical and morphological outcome measures will be analysed. No specific intervention is assigned to the subjects by the investigators of the study.
Interventions
None listed
Sponsors
German Federal Ministry of Education and Research
Charite University, Berlin, Germany
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Suspected stroke or transient ischemic attack (TIA) within 24h from symptom onset
Exclusion criteria
* MRI contraindication, age \< 18 years, intracranial hemorrhages
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical outcome measured with the National Institutes of Health Stroke Scale (NIHSS) | on follow-up examination day 5-7 | — |
| clinical outcome measured with the modified Rankin Scale (mRS) | on day 90 | conducted as telephone interview |
Secondary
| Measure | Time frame |
|---|---|
| final lesion volume (measured on FLAIR images) | on follow-up examination day 5-7 |
Other
| Measure | Time frame | Description |
|---|---|---|
| volumes of hypoperfusion on resting state-MRI perfusion maps | on follow-up examinations day 1 and 2 | outcome measure for resting state-MRI sub-project only |
| quantified values for contrast agent enhancement in the stroke lesion and on the contralateral side | on follow-up examination day 1 and 2 | outcome measure for the T1-Dynamic sub-project only |
| blood flow parameters in occluded, contralateral and (partially) recanalized vessels | on follow-up examinations day 1 and 2 | outcome measure for quantitative Angiography sub-project only |
| pH values in the region of diffusion restriction and in the region of final infarct | on follow-up examinations day 1 and 2 | outcome measure for the pH-Imaging sub-project only |
Countries
Germany
Contacts
Primary ContactJochen B: Fiebach, MD
Backup ContactKersten Villringer, MD
Outcome results
None listed